Amylyx Reports Q2 EPS of 46c, Meets Consensus Estimate

Amylyx Pharmaceuticals reported Q2 EPS of 46c, beating the consensus estimate of 45c. The company's CEOs remain encouraged by the strength of their pipeline and expect to complete recruitment in the Phase 3 LUCIDITY trial of avexitide in 2025, with topline data anticipated in the first half of 2026. They also expect to share an unblinded analysis from the Phase 2b portion of their ORION trial of AMX0035 in progressive supranuclear palsy in Q3.

Title: Amylyx Pharmaceuticals Reports Q2 EPS of $0.46, Beats Consensus Estimate

Amylyx Pharmaceuticals (NASDAQ: AMLX) reported its second-quarter (Q2) 2025 financial results on August 7, 2025, with earnings per share (EPS) of $0.46, slightly worse than the consensus estimate of $0.44. Despite the slight miss, the company's CEO remains optimistic about the strength of its pipeline and the progress of key clinical trials. The company expects to complete recruitment in the Phase 3 LUCIDITY trial of avexitide in 2025, with topline data anticipated in the first half of 2026. Additionally, the company plans to share unblinded analysis from the Phase 2b portion of its ORION trial of AMX0035 in progressive supranuclear palsy (PSP) in Q3 2025.

The quarter was marked by a GAAP net loss per share of $0.46, which was slightly wider than the consensus estimate. Research and development (R&D) expenses rose to $27.2 million, up 16.7% year-over-year, reflecting the company's focus on advancing its clinical pipeline. Operating costs fell year-over-year, with general and administrative expenses dropping by approximately 72.8% compared to Q2 2024. The net loss narrowed by 43.1% from the prior year, despite the increase in R&D costs.

Amylyx Pharmaceuticals ended the quarter with a cash position of $180.8 million, with management expecting this to last through the end of 2026. The company's focus on cost control and strategic investment in its clinical programs has extended its cash runway, providing a buffer to navigate the volatility inherent in late-stage clinical development.

The company's core pipeline includes avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH), and AMX0035, an oral combination therapy targeting cellular stress for Wolfram syndrome and PSP. The company is also developing AMX0114, an antisense oligonucleotide for amyotrophic lateral sclerosis (ALS).

Amylyx Pharmaceuticals' strategy centers on achieving clinical milestones, securing regulatory designations, and gaining approvals for its therapies. The company's success relies on intellectual property protection and targeted partnerships to support its clinical advances and eventual market entry. With no new partnerships announced in the quarter, Amylyx continues to work with existing research partners and contract manufacturers.

Investors should focus on the upcoming trial milestones, including the completion of the LUCIDITY trial for avexitide and the unblinded analysis from the ORION trial for AMX0035. The success or setbacks in these trials will determine the next phase for the company's pipeline and financial viability. Amylyx does not currently pay a dividend.

References
[1] https://www.nasdaq.com/articles/amylyx-amlx-q2-net-loss-narrows-43
[2] https://www.ainvest.com/news/amylyx-pharmaceuticals-strategic-progress-neurodegenerative-therapies-path-long-term-2508/